EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

IgG N‐ glycans are associated with prevalent and incident complications of type 2 diabetes

Elham Memarian iD, Ralph Heijmans, Roderick C Slieker iD, Adriana Sierra, Olga Gornik, Joline W J Beulens, Maja Hanic iD, Petra Elders, Julio Pascual, Eric Sijbrands iD, Gordan Lauc, Viktoria Dotz iD and 4 more

Diabetes/Metabolism Research and Reviews · 2023

DOI: 10.1002/dmrr.3685 ↗

At a glance

Journal article in Diabetes/Metabolism Research and Reviews, 2023. Written by Elham Memarian and 15 co-authors. Institution: Genos Glycoscience Research Laboratory, Zagreb, Croatia. Major MEDLINE topics: Diabetes Mellitus, Type 2, Immunoglobulin G, Polysaccharides, Diabetic Nephropathies. Cited 19 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: European Structural and Investment funding for the, Croatian National Centre of Research Excellence in Personalized Healthcare, Centre of Competences in Molecular Diagnostics, the European Regional Development Fund grant, CardioMetabolic agreement.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims/Hypothesis Inflammation is important in the development of type 2 diabetes complications. The N‐ glycosylation of IgG influences its role in inflammation. To date, the association of plasma IgG N‐ glycosylation with type 2 diabetes complications has not been extensively investigated. We hypothesised that N‐ glycosylation of IgG may be related to the development of complications of type 2 diabetes.

Methods

In three independent type 2 diabetes cohorts, plasma IgG N‐ glycosylation was measured using ultra performance liquid chromatography (DiaGene n = 1815, GenodiabMar n = 640) and mass spectrometry (Hoorn Diabetes Care Study n = 1266). We investigated the associations of IgG N‐ glycosylation (fucosylation, galactosylation, sialylation and bisection) with incident and prevalent nephropathy, retinopathy and macrovascular disease using Cox‐ and logistic regression, followed by meta‐analyses. The models were adjusted for age and sex and additionally for clinical risk factors.

Results

IgG galactosylation was negatively associated with prevalent and incident nephropathy and macrovascular disease after adjustment for clinical risk factors. Sialylation was negatively associated with incident diabetic nephropathy after adjustment for clinical risk factors. For incident retinopathy, similar associations were found for galactosylation, adjusted for age and sex.

Conclusions

We showed that IgG N‐ glycosylation, particularly galactosylation and to a lesser extent sialylation, is associated with a higher prevalence and future development of macro‐ and microvascular complications of diabetes. These findings indicate the predictive potential of IgG N‐ glycosylation in diabetes complications and should be analysed further in additional large cohorts to obtain the power to solidify these conclusions.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Immunoglobulin GPolysaccharidesDiabetic NephropathiesBiomarkersDiabetes ComplicationsHumansMaleFemaleMiddle AgedGlycosylationPrevalenceIncidenceAgedPrognosisFollow-Up StudiesRisk FactorsCohort StudiesGlycoproteins

Author keywords

biomarkerscox regressionglycobiologyischaemic heart diseasenephropathyperipheral artery disease

Substances

Immunoglobulin GPolysaccharidesBiomarkersglycosylated IgGGlycoproteins

Authors and institutions

  • Genos Glycoscience Research Laboratory, Zagreb, Croatia.
  • Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Internal Medicine, Erasmus MC - University Medical Center, Rotterdam, The Netherlands.
  • Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Epidemiology and Data Science, Amsterdam University Medical Center, Location VUMC, Amsterdam Public Health Institute, Amsterdam, The Netherlands.
  • Department of Nephrology, Hospital del Mar, Institut Mar d´Investigacions Mediques, Barcelona, Spain.

ORCID profiles: Elham Memarian, Roderick C Slieker, Maja Hanic, Eric Sijbrands, Viktoria Dotz, Leen M 't Hart, Mandy van Hoek

Funding

  • European Structural and Investment funding for the, Croatian National Centre of Research Excellence in Personalized Healthcare
  • Centre of Competences in Molecular Diagnostics
  • the European Regional Development Fund grant, CardioMetabolic agreement
  • ErasmusMC fellowship
  • FIS-FEDER-ISCIII PI16/00620
  • Strategic Plan for Research and Innovation in Health, CatSalut
  • PERIS STL008
  • The European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant for the project GlySign

Cite

APA

Memarian, E., Heijmans, R., Slieker, R. C., Sierra, A., Gornik, O., Beulens, J. W. J., Hanic, M., Elders, P., Pascual, J., Sijbrands, E., Lauc, G., Dotz, V., Barrios, C., 't Hart, L. M., Wuhrer, M., & van Hoek, M. (2023). IgG N‐ glycans are associated with prevalent and incident complications of type 2 diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3685

Vancouver

Memarian E, Heijmans R, Slieker RC, Sierra A, Gornik O, Beulens JWJ, et al. IgG N‐ glycans are associated with prevalent and incident complications of type 2 diabetes. Diabetes/Metabolism Research and Reviews. 2023. doi:10.1002/dmrr.3685

BibTeX
@article{Memarian2023,
  author = {Memarian, Elham and Heijmans, Ralph and Slieker, Roderick C and Sierra, Adriana and Gornik, Olga and Beulens, Joline W J and Hanic, Maja and Elders, Petra and Pascual, Julio and Sijbrands, Eric and Lauc, Gordan and Dotz, Viktoria and Barrios, Clara and 't Hart, Leen M and Wuhrer, Manfred and van Hoek, Mandy},
  title = {IgG N‐ glycans are associated with prevalent and incident complications of type 2 diabetes},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2023},
  doi = {10.1002/dmrr.3685}
}
Start for free →